ALCJ.PA
Crossject Société Anonyme [ALCJ.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ALCJ.PA Stock Summary
Top 10 Correlated ETFs
ALCJ.PA
Top 10 Correlated Stocks
ALCJ.PA
In the News
ALCJ.PA Financial details
Company Rating
-
Market Cap
73.25M
Income
-19.62M
Revenue
12.8M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
110
Optionable
No
Shortable
Yes
Earnings
19 Mar 2024
P/E
-18.26
Forward P/E
-
PEG
-2.36
P/S
212.62
P/B
75.87
P/C
-
P/FCF
-17.11
Quick Ratio
1.45
Current Ratio
2.58
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.55
EPS next Y
-
EPS next Q
-
EPS this Y
-25.81%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-8.57%
Revenue last 5Y
117.54%
Revenue Q/Q
182.41%
EPS Q/Q
-8.33%
-
-
-
-
SMA20
-0.84%
SMA50
60.54%
SMA100
40.48%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
798%
ROC
-0.48%
Gross Margin
-126%
Oper. Margin
-1393%
Profit Margin
-1169%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.828-5.96
52W High
-50.2%
52W Low
+149%
RSI
60.03
Rel Volume
1.9
Avg Volume
118.09K
Volume
224.54K
Perf Week
5.96%
Perf Month
20.29%
Perf Quarter
45.61%
Perf Half Y
28.35%
-
-
-
-
Beta
0.844
-
-
Volatility
0.11%, 0.13%
Prev Close
-0.4%
Price
2.49
Change
3.75%
Company Profile
- Volume Average 118.09K
- Market Capitalization 73.25M
- Employee 110
- CEO Mr. Patrick Alexandre
- Headquarters Dijon,FR
- IPO Date 2014-02-20
-
Website
https://www.crossject.com 
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
